
Good morning, HealthTech insiders. Epic holds the record for more than 325 million patients, by its own count, and on Wednesday it said that by early next year other companies' AI agents will be able to ask that record for data directly. Until now, most of the AI traffic announced around Epic has run the other way, with Epic's own agents reaching out to third-party apps.
Two other companies pushed measurement and money toward the edge of care. Sine Health said FDA cleared a way to measure essential tremor using nothing but a patient's own phone, and Hone Health took $200 million of a $228 million raise as growth financing that is repaid from the patients it signs up, not from equity. Access to the record, the measurement and the capital are each being repriced. Who pays when the traffic arrives is still open.
In today's Signal:
Epic opens the door to outside AI agents: Authorized third-party agents are expected to retrieve EHR data through MCP connections by Q1 2027.
Sine Health secures FDA clearance: Its smartphone-only essential tremor monitoring system could extend clinical measurement beyond appointments.
Hone Health raises $228M: Just $28 million is equity; the remaining $200 million finances customer acquisition and growth.
Plus: Viz.ai integrates UpToDate Expert AI, Genomics extends its Vertex partnership, and a proposed U.S. rule threatens Schedule A immigration exemptions.
The AI Work Handbook That Cuts Your Workday in Half
The 8-hour workday is becoming a 4-hour workday for people who know how to use AI.
Everyone else is still catching up.
This AI work playbook shows you exactly how to cut your work hours in half using AI.
Sign up for Superhuman AI and get:
50+ step-by-step AI tutorials to cut your workload in half — covering every part of your workday, from emails to strategy, used by 1M+ professionals at Google, Microsoft, and NASA
Superhuman AI newsletter (4 min daily) so you keep discovering new AI tools and skills to stay ahead in your career — the playbook is just the start
LATEST DEVELOPMENTS
ENTERPRISE TECH
1. Epic Plans to Open Its EHR to Outside AI Agents by 2027

Epic plans to allow authorized third-party AI agents to retrieve EHR data through MCP connections by early 2027. Image credit: Epic Systems
Epic announced on November 18 that authorized AI agents developed by other companies will be able to retrieve information from its EHR using Model Context Protocol (MCP) connections by Q1 2027. The move expands Epic's existing AI strategy from letting its own agents access external applications to allowing approved outside agents into its ecosystem.
The details:
Two-way access: Epic's Agent Factory Connectors already support outgoing integrations for agents including Emmie, Art and Penny. Incoming MCP connections are now planned for the same early-2027 period, although supported functions remain unspecified.
Platform scale: Epic reports more than 3,700 connected applications and over 1,000 free technologies available through Open.Epic.
Commercial implications: Health systems have raised concerns about rising application traffic and access costs. Epic is introducing FHIR notifications and expanded bulk-data processing to improve efficiency.
The Signal: Epic's decision could accelerate third-party healthcare AI adoption. But the competitive question is shifting from whether agents can access clinical records to who controls permissions, functionality and pricing. Those decisions will face particularly close scrutiny amid Epic's ongoing antitrust challenges.
DIGITAL DIAGNOSTICS
2. Sine Health Wins FDA Clearance for Smartphone-Only Tremor Monitoring

Sine Health has secured FDA clearance for its smartphone-only essential tremor monitoring system, enabling passive symptom tracking between clinical visits. Image credit: Sine Health / Nordic Kinetics AB
Sweden-based Sine Health announced FDA 510(k) clearance for its smartphone-based essential tremor monitoring system on November 17. The technology uses built-in phone sensors to measure tremor activity between clinical visits, potentially reducing dependence on occasional in-person assessments.
The details:
Regulatory milestone: FDA records show clearance K261026 was granted November 15, 2026. Sine describes the product as the first FDA-cleared essential tremor monitoring solution requiring only a smartphone.
Clinical application: Passive monitoring could help neurologists evaluate symptom progression and treatment response outside clinical settings.
Early evidence: A study involving 42 patients and seven controls detected 76.3% of video-confirmed tremor episodes, with strong agreement against depth-camera measurements (r = 0.975).
The Signal: Continuous, phone-based monitoring could strengthen neurological care and clinical trials, particularly as new essential tremor treatments approach regulatory decisions. However, the publicly available evidence remains limited, and FDA clearance does not establish improved clinical outcomes. Longitudinal validation and physician confidence will determine adoption.
COMMERCIAL POWER SHIFTS
3. Hone Health Raises $228M, but Only $28M Is Equity

Hone Health has secured $228 million in financing, including $200 million from General Catalyst's Customer Value Fund, to expand its longevity care platform. Image credit: Hone Health
Longevity platform Hone Health announced $228 million in financing on November 18, comprising a $28 million Series A extension led by MarcyPen Capital Partners and $200 million in growth financing from General Catalyst's Customer Value Fund. The company reports serving more than 200,000 patients.
The details:
Unusual financing: General Catalyst's $200 million facility funds customer acquisition, with returns linked to the value generated by those patients rather than conventional equity dilution.
Growth priorities: Hone plans to expand diagnostics, introduce physician-supervised peptide services and develop clinical trial infrastructure. Its new Hone Black membership includes testing across more than 1,600 health markers.
Capital allocation: The equity extension takes Hone's total equity funding to $65 million, with investment also directed toward AI-enabled clinical operations.
The Signal: The financing structure illustrates how recurring patient revenue can become an alternative source of healthcare growth capital. It preserves founder equity but makes customer retention and acquisition economics critical. For Hone, regulatory exposure in hormone, peptide and other longevity treatments adds another layer of risk.
QUICK HITS
👀 WHAT WE'RE WATCHING NEXT
Epic's MCP rollout: Developer documentation, access pricing, permitted functions and the first real-world third-party integrations before Q1 2027.
Sine Health's clinical validation: Publication of its FDA clearance summary, larger studies and the January 29, 2027 FDA target decision for Praxis's essential tremor drug.
Hone's next phase: Its peptide program, evolving FDA policies and whether customer-value financing spreads to other longevity platforms.
💰 FOLLOW THE MONEY
The deals:
Hone Health, $228M: $28 million in equity financing led by MarcyPen, alongside $200 million from General Catalyst's Customer Value Fund to support growth and customer acquisition.
VitriVax, $87M Series C: An oversubscribed round co-led by F-Prime, NEA, RA Capital Management and Sanofi Ventures to advance its single-dose Lyme disease vaccine candidate into human trials.
ODAIA, $15M Series C: Led by Monograph Capital and anchored by PHM, with an accompanying agreement making PHM its exclusive U.S. agency partner.
The pattern: Healthcare financing is increasingly combining capital with commercial infrastructure. Hone ties funding to customer economics, while ODAIA pairs investment with distribution. Investors are looking beyond product development toward scalable revenue generation.
📆 UPCOMING HEALTHTECH EVENTS
RSNA 2026 | November 29–December 3 | Chicago, USA
A major showcase for radiology innovation, imaging AI and enterprise clinical technology.GIANT Health 2026 | December 7–8 | London, UK
European digital health innovation, AI deployment and connected care.ViVE 2027 | March 14–17 | Nashville, USA
A major gathering focused on healthcare technology, enterprise AI and digital transformation.
🛠️ Trending HealthTech AI Tools
Oracle Life Sciences AI Agents: Introduced November 18, these agents monitor clinical trial performance, identify KPI variances and recommend operational actions for human review. Early-adopter access is available.
Viz.ai One + UpToDate Expert AI: Announced November 16, the integration brings contextual clinical answers directly into Viz.ai's care coordination workflows, supporting specialist decision-making.
Cognizant Patient Hub Operations: Five NVIDIA-powered AI agents automate patient inquiries, routing, translation and case summaries. Cognizant aims to reduce prescription-to-therapy timelines from approximately 30 days to fewer than seven.
🛠️ Trending HealthTech AI Startups
Helios: AI-powered preventive diagnostics
Emerged from stealth with plans to launch an at-home test measuring more than 1,000 blood proteins from a single drop, alongside an AI health coach, in 2027. Backers include Y Combinator and Formation VC.ODAIA: Predictive intelligence for pharma
Secured $15 million in Series C funding and a strategic distribution agreement with PHM to expand its AI-driven patient journey and physician targeting platform.VitriVax: Next-generation vaccine delivery
Raised $87 million to advance its single-dose Lyme disease vaccine candidate and expand its vaccine pipeline using its proprietary ALTA formulation technology.
DECISION INTELLIGENCE
Highlights: Deep Dives & Industry Reports
An examination of Epic's incoming agent architecture, the economics of EHR access, regulatory pressures and what healthcare buyers should demand before 2027.
What the FDA decision establishes, where the clinical evidence remains thin and how smartphone monitoring could influence neurology practices and drug trials.
How customer-value financing works, why subscription healthcare attracts this capital and where retention assumptions and regulatory risks could undermine the model.
Who should control access to patient-generated health data?
That's it for today!
Epic is opening new pathways into patient records, Sine is extending clinical measurement beyond hospital walls, and Hone is turning future patient revenue into growth capital. All three point toward a healthcare market where access to data, credible evidence and predictable patient relationships increasingly determine commercial power.
The unanswered question is whether these models will deliver measurable improvements in patient care, not just stronger business economics.
How did we do today?
See you tomorrow,
Dr. Dereck Mush, MD, MBA
The HealthTech Signal is independently funded. Sponsorships help us invest in better reporting, research, and a stronger newsletter for our readers. Want to reach HealthTech founders & executives while supporting the Signal? Get in touch.
Was this email forwarded to you? Sign up here.
Until tomorrow,
The HealthTech Signal



